Cargando…
An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model
BACKGROUND: Transplantation of gene transfected endothelial progenitor cells (EPCs) has provided novel methods for tumor neovascularization therapy but not for ocular disease therapy. This study aimed to investigate the efficacy of endostatin transfected EPCs in retinal neovascularization therapy. R...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392664/ https://www.ncbi.nlm.nih.gov/pubmed/32727534 http://dx.doi.org/10.1186/s12860-020-00301-1 |
_version_ | 1783564891375796224 |
---|---|
author | Ai, Jing Ma, Jian Chen, Zhi-Qing Sun, Jun-Hui Yao, Ke |
author_facet | Ai, Jing Ma, Jian Chen, Zhi-Qing Sun, Jun-Hui Yao, Ke |
author_sort | Ai, Jing |
collection | PubMed |
description | BACKGROUND: Transplantation of gene transfected endothelial progenitor cells (EPCs) has provided novel methods for tumor neovascularization therapy but not for ocular disease therapy. This study aimed to investigate the efficacy of endostatin transfected EPCs in retinal neovascularization therapy. RESULTS: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) showed the high expression of endostatin in endostatin-lentivirus-EPCs. The neovascularization leakage area and the number of preretinal neovascular cell nuclei were significantly decreased in the endostatin-lentivirus and endostatin-lentivirus-EPC groups, and the effects of these two treatments on inhibiting retinal neovascularization were almost the same. These two groups also showed the greater retinal distribution of endostatin. Intravitreal injections of endostatin-lentivirus-EPCs inhibited retinal neovascularization, vascular endothelial growth factor (VEGF) and CD31 expression, and increased endostatin expression in vivo. Endostatin-lentivirus-EPCs targeted and prevented pathologic retinal neovascularization. CONCLUSIONS: Gene-combined EPCs represent a potential new therapeutic agent for the treatment of neovascular eye diseases. |
format | Online Article Text |
id | pubmed-7392664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73926642020-08-04 An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model Ai, Jing Ma, Jian Chen, Zhi-Qing Sun, Jun-Hui Yao, Ke BMC Mol Cell Biol Research Article BACKGROUND: Transplantation of gene transfected endothelial progenitor cells (EPCs) has provided novel methods for tumor neovascularization therapy but not for ocular disease therapy. This study aimed to investigate the efficacy of endostatin transfected EPCs in retinal neovascularization therapy. RESULTS: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) showed the high expression of endostatin in endostatin-lentivirus-EPCs. The neovascularization leakage area and the number of preretinal neovascular cell nuclei were significantly decreased in the endostatin-lentivirus and endostatin-lentivirus-EPC groups, and the effects of these two treatments on inhibiting retinal neovascularization were almost the same. These two groups also showed the greater retinal distribution of endostatin. Intravitreal injections of endostatin-lentivirus-EPCs inhibited retinal neovascularization, vascular endothelial growth factor (VEGF) and CD31 expression, and increased endostatin expression in vivo. Endostatin-lentivirus-EPCs targeted and prevented pathologic retinal neovascularization. CONCLUSIONS: Gene-combined EPCs represent a potential new therapeutic agent for the treatment of neovascular eye diseases. BioMed Central 2020-07-29 /pmc/articles/PMC7392664/ /pubmed/32727534 http://dx.doi.org/10.1186/s12860-020-00301-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Ai, Jing Ma, Jian Chen, Zhi-Qing Sun, Jun-Hui Yao, Ke An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model |
title | An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model |
title_full | An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model |
title_fullStr | An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model |
title_full_unstemmed | An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model |
title_short | An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model |
title_sort | endostatin-lentivirus (es-lv)-epc gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392664/ https://www.ncbi.nlm.nih.gov/pubmed/32727534 http://dx.doi.org/10.1186/s12860-020-00301-1 |
work_keys_str_mv | AT aijing anendostatinlentiviruseslvepcgenetherapyagentforsuppressionofneovascularizationinoxygeninducedretinopathyratmodel AT majian anendostatinlentiviruseslvepcgenetherapyagentforsuppressionofneovascularizationinoxygeninducedretinopathyratmodel AT chenzhiqing anendostatinlentiviruseslvepcgenetherapyagentforsuppressionofneovascularizationinoxygeninducedretinopathyratmodel AT sunjunhui anendostatinlentiviruseslvepcgenetherapyagentforsuppressionofneovascularizationinoxygeninducedretinopathyratmodel AT yaoke anendostatinlentiviruseslvepcgenetherapyagentforsuppressionofneovascularizationinoxygeninducedretinopathyratmodel AT aijing endostatinlentiviruseslvepcgenetherapyagentforsuppressionofneovascularizationinoxygeninducedretinopathyratmodel AT majian endostatinlentiviruseslvepcgenetherapyagentforsuppressionofneovascularizationinoxygeninducedretinopathyratmodel AT chenzhiqing endostatinlentiviruseslvepcgenetherapyagentforsuppressionofneovascularizationinoxygeninducedretinopathyratmodel AT sunjunhui endostatinlentiviruseslvepcgenetherapyagentforsuppressionofneovascularizationinoxygeninducedretinopathyratmodel AT yaoke endostatinlentiviruseslvepcgenetherapyagentforsuppressionofneovascularizationinoxygeninducedretinopathyratmodel |